Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...
Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune ...
TipRanks on MSN
Alumis unveils positive phase 3 data for psoriasis drug
Alumis Inc. ( ($ALMS) ) just unveiled an announcement. On January 6, 2026, Alumis reported positive topline Phase 3 results from its ONWARD1 and ...
Stocktwits on MSN
Why is ALMS stock rising today?
The company said that envudeucitinib met all the primary and secondary endpoints in both trials. ・Across both trials, the ...
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...
Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.
Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...
Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...
On Monday, Morgan Stanley resumed its coverage of Alumis Inc. (NASDAQ:ALMS) with an Overweight rating and a $23 price target after the company’s recent merger with Acelyrin and its Q1 2025 earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback